Neurosense Therapeutics Ltd (NRSN) — Financial Flexibility Index
Neurosense Therapeutics Ltd (NRSN) has a Financial Flexibility Index of -0.71x as of December 2025. Free cash flow of $-1.83 Million (operating CF $-1.84 Million minus capex $1.50K) represents -1% of total liabilities ($2.59 Million). Check how aggressively does Neurosense Therapeutics Ltd reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Neurosense Therapeutics Ltd Financial Flexibility Index (2019–2025)
Historical Financial Flexibility Index trend for Neurosense Therapeutics Ltd across 7 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Neurosense Therapeutics Ltd.
Annual Financial Flexibility Index for Neurosense Therapeutics Ltd (2019–2025)
Year-by-year free cash flow to debt coverage for Neurosense Therapeutics Ltd. Explore NRSN operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -2.96x | $-7.66 Million | $-7.67 Million | $2.59 Million | ▲ +41.8% |
| 2024 | -5.09x | $-10.13 Million | $-10.13 Million | $1.99 Million | ▼ -202.1% |
| 2023 | -1.68x | $-8.32 Million | $-8.35 Million | $4.94 Million | ▲ +53.2% |
| 2022 | -3.59x | $-7.52 Million | $-7.59 Million | $2.09 Million | ▼ -472.7% |
| 2021 | -0.63x | $-1.52 Million | $-1.54 Million | $2.42 Million | ▲ +89.0% |
| 2020 | -5.72x | $-686.00K | $-695.00K | $120.00K | ▲ +63.2% |
| 2019 | -15.54x | $-575.00K | $-582.00K | $37.00K | — |